IPSEN (IPSEY) – What Are Brokerages Thinking About This Stock?

Shares of IPSEN (OTCMKTS:IPSEY) have been assigned a consensus recommendation of “Hold” from the seven analysts that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company.

Several research firms recently weighed in on IPSEY. Jefferies Financial Group downgraded shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Finally, HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th.

IPSEN Stock Performance

Shares of OTCMKTS IPSEY opened at $40.93 on Friday. IPSEN has a 1 year low of $32.68 and a 1 year high of $51.10. The company has a 50 day simple moving average of $44.46 and a 200-day simple moving average of $46.11.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.